Research Papers:
Prognostic and clinicopathological role of long non-coding RNA ZFAS1 in various carcinomas
Metrics: PDF 531 views | Full Text 827 views
Rui Ren1,*, Qiaoming Zhi1,*, Hugang Shen2,*, Ye Han1, Zhihua Xu1, Fei Liu3, Daiwei Wan1 and Yuting Kuang1
1Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China
2Department of General Surgery, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, 215300, China
3Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China
*These authors contributed equally to this work
Correspondence to:
Daiwei Wan, email: [email protected]
Yuting Kuang, email: [email protected]
Keywords: ZFAS1, lncRNA, cancer, prognosis, survival
Received: July 27, 2017 Accepted: October 05, 2017 Published: December 16, 2017
ABSTRACT
Accumulating evidence indicated that the lncRNA zinc finger antisense 1(lncRNA ZFAS1) expression was increased in various cancer patients. We performed a meta-analysis to determine the relationship between lncRNA ZFAS1 expression and overall survival (OS) of patients with malignant tumors. A comprehensive, computerized literature search was conducted in PubMed, Medline, Ovid, Cochrane Library and Web of Science database up to June 15, 2017. Eight eligible studies with a total of 747 cancer patients were included. The results indicated the high expression of lncRNA ZFAS1 was associated with lymph node metastasis (LNM) (OR = 2.44 CI 95 %:1.21-4.91, p = 0.012)), distant metastasis (DM) (OR = 3.46 CI 95 % :1.26-9.55, p = 0.016), TNM stage (OR = 2.80 95% CI: 1.42–5.50, p = 0.003), and poor outcome (HR = 1.52 95% CI: 1.24–1.87, p < 0.001) in both gastrointestinal and non-gastrointestinal cancer patients. In conclusion, this meta-analysis showed that lncRNA ZFAS1 associated with clinicopathological features and poor OS in different type of cancers and lncRNA ZFAS1 might serve as a novel molecular marker for predicting outcome in human cancers.